A new study from researchers at the RIKEN Center for Integrative Medical Sciences has identified associations between pathogenic variants in the BRCA1 and BRCA2 genes and four cancer types, including head and neck cancer. The findings, published in ESMO Open, add to the growing evidence that genetic testing may help refine risk assessment beyond the cancers most commonly linked to BRCA mutations.
The analysis reviewed data from 3,489 patients in BioBank Japan and compared them with 38,842 people from the same database who did not have cancer. The team focused on nine cancer types that had not previously been tested for a BRCA-gene association: bladder, bone, brain, head and neck, sarcoma, skin, testis, thyroid and ureteral cancer.
What the researchers found
According to the study, pathogenic variants in BRCA1 were linked to increased thyroid cancer risk, while BRCA2 variants were associated with higher risks of bladder, head and neck and skin cancer. The researchers also found that the impact of BRCA2 pathogenic variants on bladder cancer risk was greater in women than in men.
BRCA-related personalised medicine is already well established in breast, ovarian, pancreatic and prostate cancer, where PARP inhibitors and certain chemotherapy drugs are routinely used in clinical practice. The new results suggest that similar genetic insight may eventually help inform management strategies for some less common cancers, although the authors stressed that the study will not lead to immediate changes in surveillance recommendations.
Why the result matters for clinical practice
For clinicians, the main significance of the study is its potential to expand the list of cancers in which BRCA testing may offer useful information. The authors said the goal was to fill a gap in evidence for diseases that have received less research attention and fewer treatment options. That is especially important in head and neck cancer, where treatment decisions can be complex and outcomes vary widely depending on the stage and biological profile of the disease.
The study also highlights the continuing value of large biobank datasets in identifying patterns that may not be obvious in smaller patient groups. By comparing cancer cases with a large non-cancer cohort, researchers were able to uncover associations that could support future guideline development and more tailored approaches to care.
While the findings are encouraging, they remain an early step. Further research will be needed to confirm the associations in other populations and determine how, or whether, they should influence screening or treatment pathways in routine care. Still, the study strengthens the case for broader genetic investigation across cancers that have historically been underrepresented in precision medicine research.
Sursa foto: Imagine generată AI
